Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs Post published:December 6, 2021 Post category:Press Release
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021 Post published:November 10, 2021 Post category:Press Release
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients Post published:November 3, 2021 Post category:Press Release
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin Post published:October 27, 2021 Post category:Press Release
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson Post published:October 5, 2021 Post category:Press Release
Mydecine Completes Spin-Out of U.S. Cannabis Assets Post published:October 1, 2021 Post category:Press Release
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data Post published:September 22, 2021 Post category:Press Release
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial Post published:September 7, 2021 Post category:Press Release
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine Post published:August 18, 2021 Post category:Press Release
Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update Post published:August 17, 2021 Post category:Press Release